<DOC>
	<DOCNO>NCT02543255</DOCNO>
	<brief_summary>This study evaluate use chemotherapy cabazitaxel addition abiraterone acetate , prednisone , leuprolide neoadjuvant set prior radical prostatectomy patient high-risk prostate carcinoma . Half participant receive treatment abiraterone acetate , prednisone , leuprolide , cabazitaxel , half receive abiraterone acetate , prednisone , leuprolide .</brief_summary>
	<brief_title>Anti-Androgens Cabazitaxel Defining Complete Response Prostatectomy ( ACDC Trial )</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>Willing able provide inform consent ; Histologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature minimum 3 core positive tumour ; Tumour biopsy tissue accessible downstream evaluation ; Must candidate radical prostatectomy consider surgically resectable urologic evaluation ; High Risk D'Amico score define either PSA &gt; 20 , Gleason score ≥ 8 determine local pathologist ; T2c3 base DRE , pathologic review +/ imaging ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; No evidence metastatic disease nodal disease determine radionuclide bone scan compute tomography ( CT ) /magnetic resonance imaging ( MRI ) ; nonpathological lymph node must less 15 mm short ( transverse ) axis ; Able swallow study drug ( ) prescribe comply study requirement ; Required initial laboratory value : Absolute neutrophil count ( ANC ) ≥ 1500/μL ; Platelet count ≥ 100,000/μL ; Hemoglobin ≥ 90 g/L ; Creatinine ≤ 175 μmol/L ; Bilirubin ≤ upper limit institutional normal ( ULN ) ; AST/ALT ≤ 1.5 × ULN . Received investigational agent within 4 week prior screen ; Stage T4 prostate cancer clinical examination radiologic evaluation ; Hypogonadism severe androgen deficiency define screen serum testosterone normal range institution ; Prior androgen deprivation , chemotherapy , surgery , radiation prostate cancer ; Receiving concurrent androgen , estrogen , progestational agent , receive agent within 6 month prior randomization ; History another malignancy within previous 5 year curatively treat nonmelanomatous skin cancer nonmuscle invasive bladder cancer ; Uncontrolled intercurrent illness include , limited , ongoing active infection , cardiovascular disease , unstable angina pectoris , cardiac arrhythmia symptomatic require active therapy ; deep venous thrombosis within 3 month prior randomization ; Previous use , participation clinical trial , investigational agent block androgen synthesis ( e.g. , abiraterone acetate , TAK700 , TAK683 , TAK448 ) target androgen receptor ( e.g. , enzalutamide , BMS 641988 ) ; Liver injury disease ( e.g. , viral hepatitis , liver failure Child‐Pugh Class C ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>High risk</keyword>
</DOC>